November 22, 2016: Here are four stocks trading with relatively heavy volume among 38 equities making new 52-week lows in Tuesday’s session. On the NYSE, advancers led decliners by about 2.5 to…
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden…
Jon C. Ogg In a recent research report from Jefferies, as they do every week, the analysts highlight their top value ideas to buy now.
Tuesday’s top analyst upgrades, downgrades and initiations include AT&T, Capital One, Cisco, Novartis, Sprint and Starbucks.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Capital One, Energen, Micron Technology, Salesforce.com, United Continental, United Rentals and Viacom.
The top analyst upgrades, downgrades and initiations seen on Wednesday, March 23, include Charles Schwab, Dean Foods, HollyFrontier, Incyte, Newfield Exploration and Nike.
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
Here are four stocks that will help you sleep easy regardless of how the broader indexes perform for the rest of this year.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss…
Jon C. Ogg Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
Chris Lange 
